Ones To Watch News
Refine Search
Pharmaceutical
Anglo-Irish rare diseases specialist Amryt Pharma (LSE: AMYT) has won a positive reimbursement decision in the UK for Myalepta (metreleptin). 20 January 2021
Biotechnology
A subsidiary of US pharma major Eli Lilly and Dutch biotech Merus have announced a research collaboration and exclusive license agreement. 19 January 2021
Biotechnology
US AAV-based gene therapies developer Taysha Gene Therapies today announced that it has received both rare pediatric disease and orphan drug designations from the US Food and Drug Administration for TSHA-105, an AAV9-based gene therapy in development for SLC13A5-related epilepsy. 19 January 2021
Biotechnology
Munich-based gene therapy specialist ViGeneron has announced a research collaboration with Japan’s Daiichi Sankyo. 18 January 2021
Pharmaceutical
NewAmsterdam Pharma (NAP), a Dutch clinical-stage company focused on the research and development of transformative therapies for cardio-metabolic diseases, has completed an oversubscribed 160 million-euro ($196 million) Series A funding round. 14 January 2021
Biotechnology
French pharma major Sanofi today revealed it has entered into an agreement under which it will acquire British privately-held biotech Kymab, which is focused on immune-mediated diseases and immuno-oncology therapeutics. 11 January 2021
Biotechnology
US biotech DiCE Molecules, which is leveraging its proprietary DNA-encoded library platform to discover and develop next-generation therapeutics in immunology, has announced the completion of an $80 million Series C financing. 11 January 2021
Biotechnology
Privately-held cell therapy developer ArsenalBio has entered into a multi-year discovery collaboration with Bristol Myers Squibb to advance next-generation T-cell therapies for the treatment of solid tumors. 8 January 2021
Pharmaceutical
USA-based Mycovia Pharmaceuticals has announced positive top-line results from the Phase III ultraVIOLET trial of oteseconazole. 6 January 2021
Biotechnology
Leaps by Bayer has led a $105 million Series B financing round in the gene circuit company, Senti Biosciences. 6 January 2021
Biotechnology
A2 Biotherapeutics has entered into an agreement with pharma giant Merck & Co, whereby A2 will continue research and pre-clinical development of its undisclosed Tmod cell therapy candidate. 24 December 2020
Pharmaceutical
CNS specialist Prilenia Therapeutics has announced the publication of additional analyses of pridopidine in Huntingdon’s disease. 18 December 2020
Biotechnology
Sio Gene Therapies has reported positive six-month follow-up data from the low-dose cohort of the company’s dose escalation study of AXO-AAV-GM1, its adeno-associated viral vector (AAV)9-based gene therapy for the treatment of GM1 gangliosidosis. 16 December 2020
Pharmaceutical
UK provider of development services to drugmakers Ergomed today announced the acquisition of MS Clinical Services (MediSource), a specialized clinical research organization (CRO) based in Houston, Texas, USA. 14 December 2020
Biotechnology
US biotech Syros Pharmaceuticals has acquired SY-2101, a clinical-stage drug candidate formerly known as ORH-2014, from Orsenix. 7 December 2020
Biotechnology
Germany’s Bayer and US biotech Atara Biotherapeutics today announced an exclusive worldwide license agreement and research, development and manufacturing collaboration for mesothelin-directed CAR-T cell therapies for the treatment of solid tumors, with news of the deal pushing Atara’s shares up 10.6% to $27.20 pre-market. 7 December 2020
Pharmaceutical
Shares of Australia’s Noxopharm closed down 10.16% at A$0.57 today, despite announcing encouraging news with its investigational drug Veyonda (idronoxil). 3 December 2020
Biotechnology
Genomics-based drug discovery company Exelixis has exercised its exclusive option for Iconic Therapeutics’ lead oncology antibody-drug conjugate (ADC) program under a May 2019 agreement that also involves Zymeworks. 2 December 2020
Biotechnology
Shares of USA-based Moleculin Biotech shot up more than 33% to $1.04 yesterday, after in revealed that the US Food and Drug Administration has approved its request for a Rare Pediatric Disease (RPD) designation for its drug candidate WP1066. 2 December 2020
Biotechnology
Privately-held Scottish biotech ILC Therapeutics has secured an investment from Medical Incubator Japan, a Tokyo-based fund specializing in healthcare. 1 December 2020
Biotechnology
Epitopea, a UK and Canada-based cancer immunotherapeutics company, has partnered with nucleic acid delivery specialist Genevant Sciences to develop new RNA-based therapies targeting proprietary tumor antigens. 20 December 2024
Pharmaceutical
US biotech Assembly Biosciences has announced an equity investment of $20.1 million by Gilead Sciences to purchase additional common stock in the company and an amendment to their collaboration to advance the research and development of novel antiviral therapies with $10 million in accelerated funding. 20 December 2024
Pharmaceutical
Privately-held Xcovery Holdings, an oncology-focused pharma company, has announced that the US Food and Drug Administration (FDA) has approved Ensacove (ensartinib) for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). 19 December 2024
Biotechnology
Privately-held biotech Ottimo Pharma today announces the completion of a Series A financing round of over $140 million. 19 December 2024
Biotechnology
Safi Biotherapeutics, a specialist in stem-cell derived red blood cell products, has received Rare Pediatric Disease designation and Orphan Drug designation from the US regulator. 19 December 2024
Biotechnology
BioAge Labs today announced a multi-year research collaboration with Swiss pharma giant Novartis, with the news pushing the US biotech’s shares up 6.1% to $4.35 by early afternoon. 18 December 2024
Pharmaceutical
Marking its second deal this month alone, Novo Nordisk has entered into a multi-year collaboration with Massachusetts, USA-based Photys Therapeutics to develop novel proximity-based therapeutics for a cardiometabolic disease target. 18 December 2024
Biotechnology
Cara Therapeutics and Tvardi Therapeutics have announced a definitive agreement to merge, creating a new entity under the Tvardi name. 18 December 2024
Pharmaceutical
SiteOne Therapeutics has announced the completion of a $100 million series C financing, led by Novo Holdings, with participation from OrbiMed, Wellington Management, Mission BioCapital, and others. 18 December 2024
Biotechnology
Flagship Pioneering-founded genome engineering biotech Tessera Therapeutics today announced an investment of up to $50 million from the Bill & Melinda Gates Foundation to develop curative, globally accessible in vivo genetic therapies for sickle cell disease. 18 December 2024
Biotechnology
San Francisco-based Indapta Therapeutics, a privately held start-up developing next-generation cell therapies, has raised $22.5 million in a new financing round. The firm raised over $50 million in series A funding in 2022. 18 December 2024
Biotechnology
French CNS specialist Theranexus saw its shares leap more than 34% to 0.65 euros as it revealed a license and supply agreement with Exeltis to commercialize TX01, its novel formulation of a compound already approved in the indication for the treatment of rare neurological diseases. 18 December 2024
Biotechnology
Shares in US biopharma Viridian Therapeutics shot up by 21% on Monday. 17 December 2024
Biotechnology
US antivirals giant Gilead Sciences today revealed it has entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets with Californian biotech Terray Therapeutics. 17 December 2024
Pharmaceutical
Swedish biotech company Inify Laboratories has raised approximately 135 million kroner ($12.3 million) through a private placement, supporting a planned expansion into the UK. 16 December 2024
Biotechnology
Dewpoint Therapeutics and ConcertAI have announced the first phase of their translational oncology partnership, aligned around the former company's latest drug candidate, DPTX3186. 16 December 2024
Biotechnology
Bicycle Therapeutics, a UK-headquartered pharma company developing a new class of therapeutics based on its proprietary bicyclic peptide technology, closed a third lower on Friday. 16 December 2024
Biotechnology
In a filing with the US financial regulator, German mRNA specialist BioNTech has noted the lifting of a partial clinical hold on its PRESERVE-003 trial. 16 December 2024
Biotechnology
VectorY Therapeutics, a Netherlands-based biotech focused on neurodegenerative diseases, has appointed Jim Scibetta as chief executive officer. 16 December 2024
Biotechnology
Sino-American biotech BeiGene has announced it has entered into a global licensing agreement with China’s CSPC Zhongqi Pharmaceutical Technology for SYH2039, a novel methionine adenosyltransferase 2A (MAT2A)-inhibitor being explored for solid tumors. 13 December 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze